• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » invivodata consults on ClinRO instrument for UCB

invivodata consults on ClinRO instrument for UCB

May 11, 2012
CenterWatch Staff

Pittsburgh, Penn.-based invivodata, a fully-integrated clinical outcomes assessments company, has been chosen to deliver regulatory consulting services for a phase III trial that UCB is conducting in the development of a unique biopharmaceutical product to treat Rheumatoid Arthritis (RA).

UCB is adhering to recent statements issued by FDA indicating that researchers need to ensure all measurements and outcomes reflect what is actually happening with the patient. Specifically, instruments based upon a clinician’s evaluation of a patient (ClinROs), and measures taken by an observer (ObsROs), like a mother reporting about her child, are subject to the same requirements for reliability and validity as Patient Reported Outcomes (PROs), as delineated in the PRO Guidance.

UCB’s trial protocol includes the Assessment of Joint Tenderness/Pain and Swelling (TSJ/C), a commonly used ClinRO instrument which clinicians use to document tenderness/pain and swelling during physical examination of a patient. UCB is migrating or moving the TSJ/C from the traditional paper-based administration to an electronic tablet, invivodata’s SITEprotablet.

Consistent with FDA recommendations, UCB has contracted with invivodata to demonstrate that the use of an electronic tablet will not affect how clinicians interpret and use the TSJ/C instrument. invivodata’s scientists and regulatory experts will conduct cognitive interviews of clinicians to establish that electronic administration of the TSJ/C is equivalent to traditional, paper-and-pencil administration.

“Since electronic COA data will be the basis of our labeling claims, we needed a partner with not only technological expertise, but one who fully understands the evolving changes in U.S. and European regulations,” said Geoffroy Coteur, senior health outcomes manager, UCB. “We chose to work with invivodata based on their unique, integrated approach to developing, implementing and justifying effective COA strategies.”

Dr. Jean Paty, invivodata co-founder, chief scientist and regulatory officer, said, “To our knowledge, this is the first example of a ClinRO instrument going through a regulatory-driven migration process. We applaud UCB for their pioneering efforts to ensure all of their COA instruments meet the regulatory standard of well-defined and reliable instruments.”

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing